Michael E. Abram
About
Michael E. Abram is a scholar working on Infectious Diseases, Virology and Molecular Biology.
According to data from OpenAlex, Michael E. Abram has authored 36 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 21 papers in Virology and 8 papers in Molecular Biology. Recurrent topics in Michael E. Abram's work include HIV/AIDS drug development and treatment (24 papers), HIV Research and Treatment (21 papers) and HIV/AIDS Research and Interventions (11 papers). Michael E. Abram is often cited by papers focused on HIV/AIDS drug development and treatment (24 papers), HIV Research and Treatment (21 papers) and HIV/AIDS Research and Interventions (11 papers). Michael E. Abram collaborates with scholars based in United States, United Kingdom and France. Michael E. Abram's co-authors include Andrew Cheng, W. Gregory Alvord, Andrea L. Ferris, Stephen H. Hughes, Wei Shao, Michael A. Parniak, Marshall W. Fordyce, Kirsten White, Nicolas Margot and Hans‐Dieter Klenk and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and PLoS ONE.
In The Last Decade
Michael E. Abram
36 papers receiving 1.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Michael E. Abram United States | 20 | 1.1k | 751 | 431 | 344 | 276 | 36 | 1.6k | ||
| Manish Sagar United States | 23 | 1.4k 1.3× | 1.5k 1.9× | 477 1.1× | 355 1.0× | 113 0.4× | 69 | 2.3k | ||
| David Anderson United States | 19 | 417 0.4× | 468 0.6× | 288 0.7× | 117 0.3× | 109 0.4× | 45 | 1.0k | ||
| J. M. A. Lange Netherlands | 14 | 1.2k 1.1× | 1.3k 1.7× | 343 0.8× | 101 0.3× | 154 0.6× | 22 | 1.7k | ||
| Wayne B. Dyer Australia | 24 | 812 0.7× | 1.5k 2.0× | 493 1.1× | 389 1.1× | 152 0.6× | 52 | 2.3k | ||
| André Inwoley Ivory Coast | 14 | 640 0.6× | 459 0.6× | 423 1.0× | 140 0.4× | 130 0.5× | 28 | 1.2k | ||
| Daniela Moïsi Canada | 27 | 2.4k 2.1× | 2.2k 3.0× | 654 1.5× | 245 0.7× | 154 0.6× | 68 | 2.6k | ||
| Moraima Guadalupe United States | 13 | 570 0.5× | 1000 1.3× | 468 1.1× | 264 0.8× | 234 0.8× | 13 | 1.6k | ||
| Xiaoxu Han China | 24 | 1.1k 1.0× | 1.1k 1.5× | 561 1.3× | 208 0.6× | 60 0.2× | 162 | 2.0k | ||
| Edward D. Blair United Kingdom | 15 | 482 0.4× | 512 0.7× | 366 0.8× | 266 0.8× | 34 0.1× | 28 | 1.1k | ||
| Robert Yarchoan United States | 16 | 833 0.7× | 787 1.0× | 428 1.0× | 174 0.5× | 104 0.4× | 20 | 1.4k |
Countries citing papers authored by Michael E. Abram
Since
Specialization
Citations
This map shows the geographic impact of Michael E. Abram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Abram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Abram more than expected).
Fields of papers citing papers by Michael E. Abram
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael E. Abram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Abram. The network helps show where Michael E. Abram may publish in the future.
Co-authorship network of co-authors of Michael E. Abram
This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Abram. A scholar is included among the top collaborators of Michael E. Abram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Abram. Michael E. Abram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wilkins, Deidre, Yuan Yuan, Yue Chang, et al.. (2023). Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Nature Medicine. 29(5). 1172–1179.
2.
O’Toole, Áine, Oliver G. Pybus, Michael E. Abram, Elizabeth J. Kelly, & Andrew Rambaut. (2022). Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences. BMC Genomics. 23(1). 121–121.
3.
Tabor, David E., Fiona Fernandes, Annefleur C Langedijk, et al.. (2020). Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017−2018 INFORM-RSV Study. Journal of Clinical Microbiology. 59(1).
4.
Li, You, Harry Campbell, Harish Nair, et al.. (2020). Unveiling the Risk Period for Death After Respiratory Syncytial Virus Illness in Young Children Using a Self-Controlled Case Series Design. The Journal of Infectious Diseases. 222(Supplement_7). S634–S639.
5.
Ram, Renee R., Nicolas Margot, Michael E. Abram, et al.. (2019). Activation of HIV-Specific CD8+ T-cells from HIV+ Donors by Vesatolimod. Antiviral Therapy. 25(3). 163–169.
6.
Abram, Michael E., Renee R. Ram, Nicolas Margot, et al.. (2017). Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. PLoS ONE. 12(2). e0172206–e0172206.
7.
Margot, Nicolas, Pamela Wong, Rima Kulkarni, et al.. (2017). Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide. The Journal of Infectious Diseases. 215(6). 920–927.
8.
Gallant, Joel E., Eric S. Daar, François Raffi, et al.. (2016). Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. The Lancet HIV. 3(4). e158–e165.
9.
Pozniak, Anton, José Ramón Arribas, Joseph Gathe, et al.. (2016). Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas).
10.
Post, Frank A., Pablo Tebas, Amanda Clarke, et al.. (2016). Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 74(2). 180–184.
11.
Pozniak, Anton, José Ramón Arribas, Joseph Gathe, et al.. (2015). Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 71(5). 530–537.
12.
Gallant, Joel E., Ellen Koenig, Jaime Andrade‐Villanueva, et al.. (2015). Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes. 69(3). 338–340.
13.
Post, Frank A., Jonathan Winston, Jaime Andrade‐Villanueva, et al.. (2014). Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 68(3). 310–313.
14.
Kulkarni, Rima, Michael E. Abram, Damian J. McColl, et al.. (2014). Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients. HIV Clinical Trials. 15(5). 218–230.
15.
McDonald, Cheryl, Claudia Martorell, Moti Ramgopal, et al.. (2014). Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment. HIV Clinical Trials. 15(6). 269–273.
16.
Rockstroh, Jürgen K., Edwin DeJesus, Keith Henry, et al.. (2013). A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(5). 483–486.
17.
Abram, Michael E., Andrea L. Ferris, Wei Shao, W. Gregory Alvord, & Stephen H. Hughes. (2010). Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication. Journal of Virology. 84(19). 9864–9878.
18.
Abram, Michael E. & Michael A. Parniak. (2005). Virion Instability of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Mutated in the Protease Cleavage Site between RT p51 and the RT RNase H Domain. Journal of Virology. 79(18). 11952–11961.
19.
Arion, Dominique, Nicolas Sluis‐Cremer, Kyung‐Lyum Min, et al.. (2002). Mutational Analysis of Tyr-501 of HIV-1 Reverse Transcriptase. Journal of Biological Chemistry. 277(2). 1370–1374.
20.
Hasinoff, Brian B., et al.. (2001). The Catalytic DNA Topoisomerase II Inhibitor Dexrazoxane (ICRF-187) Induces Differentiation and Apoptosis in Human Leukemia K562 Cells. Molecular Pharmacology. 59(3). 453–461.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Manish Sagar Breakdown of academic impact, for papers by David Anderson Breakdown of academic impact, for papers by J. M. A. Lange Breakdown of academic impact, for papers by Wayne B. Dyer Breakdown of academic impact, for papers by André Inwoley Breakdown of academic impact, for papers by Daniela Moïsi Breakdown of academic impact, for papers by Moraima Guadalupe Breakdown of academic impact, for papers by Xiaoxu Han Breakdown of academic impact, for papers by Edward D. Blair Breakdown of academic impact, for papers by Robert Yarchoan